Skip to Main Content
Brown University
School of Public Health Brown University

Center for Health System Sustainability

Search Menu

Site Navigation

  • Home
  • About
  • Research
    • Health System Performance Assessment
    • Improving Care Delivery
    • Pharma Policy
    • Health & Wealth
  • People
  • Network
  • Publications
  • Impact
  • Events
    • Past Events
Search
Center for Health System Sustainability

Publications

The latest publications from the Center for Health System Sustainability

Publications

The latest publications from the Center for Health System Sustainability

See more CHeSS publications
Schizophrenia Bulletin

Weight Loss in Veterans with Schizophrenia and Multimorbidity Prescribed Semaglutide: Results From a National Retrospective Cohort Study

August 17, 2025
People with schizophrenia are at heightened risk for physical multimorbidity and premature death. Semaglutide improves cardiometabolic outcomes, yet research is limited among individuals with schizophrenia. This study explored weight loss in Veterans with schizophrenia and physical multimorbidity (ie, heart failure and diabetes) prescribed semaglutide and compared weight changes to those in Veterans without schizophrenia. We hypothesized that those with schizophrenia would experience less weight loss compared to those without schizophrenia.

Read Article
Health Economics

The Impact of Multimarket Competition on Generic Drugs' Regulated Prices

August 16, 2025
Competition between firms selling similar drugs is often fostered by policymakers as a means to curb pharmaceutical spending. While firms may compete within these specific drug markets, they also repeatedly encounter rival firms in different markets. This may shape competitive dynamics within and between markets. Yet, multimarket contacts, particularly relevant for multiproduct firms such as pharmaceutical companies, are often overlooked by pricing regulations. This paper investigates how multimarket contacts influence competition between pharmaceutical firms in off-patent markets. Using detailed product-level information on all retail pharmacy sales of generic statin drugs, we quantify the universe of multimarket contacts between firms in these off-patent markets, in Portugal, between 2015 and 2017. We then assess how multimarket contacts affect price competition. To do so, we explore the strict price regulation in Portuguese generic drug markets. Specifically, the Portuguese Internal Reference Pricing System (RPS) defines a price cap for each generic drug. Rather than examining absolute drug prices, we quantify the degree of price competition as the ratio between a firm's drug price and its regulatory price cap (price-to-cap ratio). We find that firms with more multimarket interactions set prices closer to price caps, consistent with the mutual forbearance hypothesis. This effect persists after controlling for brand status, lagged market share, and is not explained by common ownership. Our main results are consistent across alternative model specifications. However, due to limited within-firm variation over time, the effect is not significant in system generalized method of moment instrumental variable estimates. These results suggest that price caps may act as coordination anchors, thus lowering price competition between firms. Policymakers should consider targeted price cap adjustments as safeguards to preserve competition in off-patent drug markets.

Read Article
JAMA Health Forum

Prices and Affordability of Essential Medicines in 72 Low-, Middle-, and High-Income Markets

August 15, 2025
Equitable access to essential medicines, which the World Health Organization (WHO) defines as those that meet the priority needs of the population,1 is key to achieving universal health care coverage.(2) However, it is estimated that essential medicines are unaffordable or unavailable to 1 in 4 people worldwide.(3) As governments strive to achieve universal access to essential medicines, it is important to understand how the prices and affordability of these medicines vary between countries. High drug prices strain both personal and government budgets, especially in low- and middle-income countries, where patients often face high out-of-pocket costs.

Although many national surveys of medicine prices and affordability have been conducted, fewer analyses have compared these variables internationally, with most research dating back to 2011 or earlier.(4-20) Many of these studies have focused on high-income countries. Of the studies that also included low- and middle-income nations, most compared the prices of 15 or fewer medicines or included a small number of countries, limiting the generalizability of those findings. Therefore, little is known about the relationship between national income and drug prices. The question remains whether some poor countries routinely pay more than rich countries for the same prescription drugs, possibly owing to weaker pharmaceutical pricing policies.

This cross-sectional study used global data on pharmaceutical sales to compare the list prices of 549 essential medicines in 72 high-, middle-, and low-income markets (covering 87 countries) in 2022, both in nominal and purchasing power–adjusted terms. We also evaluated the affordability of 8 essential medicines used to treat major causes of death and disability globally.

Read Article
JAMA Network

Lowering Drug Prices in the US—Look Within, Not Abroad

July 28, 2025
On May 12, 2025, the Trump administration issued an executive order to lower prescription drug costs by mandating that the US pay no more than prices in peer countries. The legality of implementing this so-called most favored nation (MFN) pricing through executive action is unclear. However, the idea of benchmarking US drug prices to prices in other countries is not new. The Trump administration unsuccessfully attempted a more limited MFN policy during its first term, and a 2019 bill passed by House Democrats used international prices as upper limits for Medicare price negotiations. Although lowering drug prices is a priority, achieving this by linking prices in the US to those in other countries is a misguided approach built on a misdiagnosis of the reason prices are higher in the US than in other countries.
Read Article
The New England Journal of Medicine

Response to the Editors - Wealth and Mortality in the United States and Europe

July 9, 2025
The responses to our study on wealth and mortality in the United States and Europe raise important questions about causal inference, potential confounding, and the interpretation of cross-national differences. As noted by the correspondents, our findings reflect associations, not causal relationships. Although the patterns we observed were consistent across settings, more work is needed to disentangle the complex relationship between wealth and health.
Read Article
Health Affairs

New Cancer Drug Approvals: Less Than Half Of Important Clinical Trial Uncertainties Reported By The FDA To Clinicians, 2019–22

July 7, 2025
Uncertainties about the benefits and harms of new drugs are common at the time of drugs’ approval. It is unclear to what extent the Food and Drug Administration (FDA) communicates these uncertainties in the FDA-approved prescribing information (the drug label), which is the primary channel of communication between the FDA and physicians. Although physicians might not regularly consult the drug label for prescribing decisions, other information sources used by physicians either index or incorporate information from the label. We searched FDA review documents for uncertainties identified by FDA reviewers with new cancer drugs. We considered the subset of uncertainties highlighted in the FDA’s Benefit-Risk Framework as important to the FDA’s approval decision. During the period 2019–22, the FDA approved fifty-two new cancer drugs. In review documents, FDA reviewers identified a total of 213 clinical trial uncertainties with new cancer drugs, 50 percent of which were considered to be important uncertainties to the FDA’s approval decision. Labels for physicians reported information on 26 percent of all uncertainties and 48 percent of uncertainties that were important to the FDA’s approval decision. Communicating uncertainties about the evidence of drugs in the label is essential for informing physicians about drugs’ safe and effective use.
Read Article
Health Affairs Scholar

Geographical variation in physician supply and its relationship to utilization of care across older adults in the United States

June 30, 2025
Scholars express concern that general practitioner shortages and specialist surpluses induce overspecialization, with overuse of costly specialist services and underuse of cost-effective primary care services. Yet few studies directly assess the relationship between physician supply and patient utilization. Given this gap, this paper examines the associations between physician supply, care utilization, and patient need and whether patients use more specialists in areas with lower primary care supply.
Read Article
The Lancet

Population health impact of NICE-recommended new drugs – Authors' reply

June 28, 2025
We appreciate the responses to our Article, which suggest that the health cost of paying for new pharmaceuticals in the National Health Service (NHS), estimated at £1·25 million quality-adjusted life-years (QALYs) lost between 2000 and 2020, might be justified by the benefits of incentivising future innovation, attracting industry funding, or prioritising certain populations—we disagree.
Read Article
Journal of the Intensive Care Society

Geographical disparities in adult intensive care beds in the English National Health Service: A retrospective, observational panel data study

June 26, 2025
The English National Health Service (NHS) is a publicly funded system, however significant disparities in provision exist. Whereas the national picture of the distribution of Intensive Care Unit (ICU) beds has increased over time, less is understood about the regional variation in the rate of growth in ICU services and whether this is related to population growth. The aim of this study was to describe the national variation in the supply of ICU beds in England and evaluate whether there has been a narrowing of the regional disparities in providing ICU beds over time.
Read Article
European Journal of Public Health

Examining systemic differences in mortality after hip repair: a comparative analysis of 30- and 180-day adjusted mortality rates in five health systems

June 26, 2025

Outcomes after a hip repair in the older adult population are highly dependent on patients’ characteristics. However, contextual factors such as the hospital of treatment may have an impact not sufficiently studied. We aimed to elicit the effect of hospital providers on all-cause-adjusted mortality rates after hip fracture repair. Observational study on virtually all potentially eligible hip fracture patients treated in 2240 hospitals from Ontario (Canada), Aragon (Spain), Finland, Sweden, and the USA (40 states). The primary endpoint was the risk-adjusted all-cause mortality after hip repair measured 30 days and 180 days after surgery. Following a federated approach, GAMM-logit models were run for each region. Median odds ratio (MOR) were estimated to elicit the variation at hospital level. The study included 535 519 hip repairs. The overall predicted 30-day adjusted mortality rate was 40.5 per 1000 hip repair episodes; 136.3 per 1000 hip repair episodes in the 180-day adjusted mortality rate. 30- and 180-day adjusted mortality rates were larger within the regions than across regions. Variance in patients’ mortality at the hospital provider accounted for MOR: 1.43 in 30-day mortality and MOR: 1.35 in 180-day mortality. Beyond differences in the individual risk of death, our study found wide systemic variations in mortality rates in older adult patients exposed to hip fracture repair attributable to the hospital of treatment. Our results call for a reorientation of care pathways after hip repair in frail patients, both in the short- and the long-term.
Read Article
Health Affairs Forefront

Making Health Spending Sustainable Means Targeting Increasingly Excessive Price Growth

June 25, 2025
In the most recent National Health Expenditure (NHE) Projections, for 2024-33, Sean Keehan and colleagues at the Centers for Medicare and Medicaid Services (CMS) predict strong growth in health care expenditures in 2024, and average annual growth over the entire projection period that exceeds growth in GDP. According to their projections, health care is set to comprise 20.3 percent of GDP by 2033. This increase in health spending is expected despite declines in coverage, prompted by the continued unwinding of Medicaid pandemic policies and lower enrollment in private insurance stemming from the expiration of the IRA’s temporarily enhanced premium tax subsidies for Marketplace plans.
Read Article
The Joint Commission Journal on Quality and Patient Safety

Patient Safety Metrics Monitoring Across Harvard-Affiliated Hospitals: A Mixed Methods Study

May 17, 2025
The past two decades have seen a surge in available patient safety metrics. However, the variability in how healthcare organizations choose and monitor these metrics remains unknown. We cataloged the metrics organizations chose and how actively they monitored them. We investigated factors influencing the monitoring of patient safety metrics using surveys and in-depth interviews with patient safety experts from 11 Harvard-affiliated organizations.
Read Article

CHeSS in the News

See all the announcements
May 19, 2025 AcademyHealth

Publication-of-the-Year Award 2025

The Publication-of-the-Year Award recognizes the best and most relevant peer-reviewed, scientific work that the fields of health services research and health policy have produced and published in the prior calendar year.

Publication-of-the-Year Award
Differential Legal Protections for Biologics Vs Small-Molecule Drugs in the U.S.
Olivier J. Wouters, Ph.D.
April 16, 2025 The Economist

How Britain decides which drugs to buy

Since 1999, the National Institute for Health and Care Excellence has weighed costs against benefits to help the NHS decide what it should buy. The institute’s boss, Sam Roberts, calls it a mindful “health-care innovation shopper”. Within a fixed budget, every new drug it buys risks squeezing essentials like GPs or ambulances among existing health-care services.
March 26, 2025 STAT+

Recent pharma-telehealth partnerships feel ‘black boxy,’ and why that’s problematic

In recent months, a new kind of partnership between telehealth companies and pharmaceutical manufacturers has come under scrutiny over concerns that such arrangements could lead to inappropriate prescriptions and poor care. Eli Lilly and Pfizer, along with five telehealth companies accessible through the pharma companies’ websites, have recently received letters from four senators echoing those concerns, asking questions about care, prescription volume, and the flow of data and money between the firms. The lawmakers want to determine whether pharma-telehealth deals may be violating the federal anti-kickback statute. That question has also piqued the interest of three health policy researchers at Brown University.
July 1, 2024 Bulletin of the World Health Organization

Policy Approaches to Health System Performance Assessment

The articles in this issue highlight the importance of regular health systems performance assessment to inform policies that advance progress on health system objectives globally, and offer insights on associated data, methods and applications.
June 4, 2024 Science Business

Global research needs transnational funding

As common problems call for more global cooperation in research, cross-border partnerships struggle to get money from national funding agencies
March 2, 2024 APES

Health Policy Analysis of Portuguese Electoral Programs

Sara Machado Ph.D. uses the HSPA framework to examine the health policy propositions being debated by parties in the 2024 Portuguese legislative elections.
January 29, 2024 STAT

Which country has the best health care? That’s the wrong question

Irene Papanicolas: Every health care model involves people doing their best to balance competing priorities in the face of limited resources. In other words, every system involves tradeoffs.
November 10, 2021 The Guardian

England has highest death rates of older patients in western world, study finds

ICCONIC findings featured in a Guardian article.
November 10, 2021 The Health Foundation

Caring for older patients with complex needs: How does England compare with 11 OECD countries?

Report of ICCONIC research to the Health Foundation.
Brown University School of Public Health
Providence RI 02903 401-863-3375 public_health@brown.edu

Quick Navigation

  • Newsletter
  • Visit Brown
  • Campus Map

Footer Navigation

  • Accessibility
  • Careers at Brown
Give To Brown

© Brown University

School of Public Health Brown University
For You
Search Menu

Mobile Site Navigation

    Mobile Site Navigation

    • Home
    • About
    • Research
      • Health System Performance Assessment
      • Improving Care Delivery
      • Pharma Policy
      • Health & Wealth
    • People
    • Network
    • Publications
    • Impact
    • Events
      • Past Events
All of Brown.edu People
Close Search

Publications